DYN
Dyne Therapeutics, Inc.
Key Financials
Operating Income
$-468184000
↓ 36.1%
Shareholders' Equity
$972.1M
↑ 54.3%
Total Assets
$1.2B
↑ 71.7%
EPS (Diluted)
$-3.47
↓ 3.0%
Cash & Equivalents
$893.4M
↑ 105.2%
Net Income
$-446214000
↓ 40.6%
Total Liabilities
$214.8M
↑ 249.9%
Operating Cash Flow
$-403207000.00
↓ 37.9%
Recent SEC Filings
| Form Type | Filed Date | Link |
|---|---|---|
| 4 | 4/17/2026 | View on SEC |
| PRE 14A | 4/9/2026 | View on SEC |
| 4 | 4/3/2026 | View on SEC |
| 4 | 4/1/2026 | View on SEC |
| 144 | 4/1/2026 | View on SEC |
| S-8 | 3/27/2026 | View on SEC |
| SCHEDULE 13G/A | 3/26/2026 | View on SEC |
| 4 | 3/13/2026 | View on SEC |
| 4 | 3/13/2026 | View on SEC |
| 4 | 3/11/2026 | View on SEC |
Company Information
| Field | Value |
|---|---|
| Ticker | DYN |
| Company Name | Dyne Therapeutics, Inc. |
| CIK | 1818794 |
| Sector | Pharmaceutical Preparations |
| Industry | Large accelerated filer |
| Exchange | Nasdaq |
| SIC Code | 2834 |
| SIC Description | Pharmaceutical Preparations |
| Entity Type | operating |
| Fiscal Year End | 1231 |
| State of Incorporation | DE |
| Phone | (781) 786-8230 |